Paris, November 23rd, 2010 - Bryan, Garnier and Co, the independent pan-European investment bank focused on growth companies, today announces the successful closing of a c.€50 million initial public offering for Zealand Pharma.
Zealand Pharma today completed its initial public offering and listed on the NASDAQ OMX Copenhagen Stock Exchange. In the IPO, the company issued approximately 4.3 million new shares at an offer price of DKK 86 (EUR 11.5) per new share, raising gross proceeds of approximately DKK 373 (€50) million. The offering involved retail investors in Denmark as well as Danish and international institutional investors. Bryan, Garnier & Co acted as co-lead manager on this transaction.
For more information, please contact:
Christian Finan - Director - Equity Capital Markets / +33 (0)1 56 68 75 30 / email@example.com
Jean-Christophe Renondin - Managing Director - Healthcare / +33 (0)1 56 68 75 04 / firstname.lastname@example.org
About Zealand Pharma
Zealand Pharma A/S is
a biotechnology company based in Copenhagen, Denmark. Zealand Pharma
specializes in the discovery, optimization and development of novel peptide
drugs and has a broad and mature pipeline of drug candidates identified through
its own drug discovery activities. The company’s focus lies in the field of
diabetes/metabolic diseases, and its lead drug invention is lixisenatide, a
once-daily GLP-1 agonist, which is licensed to Sanofi for the treatment of Type
2 diabetes. Lixisenatide is currently under regulatory review in a large number
of countries globally.
Zealand Pharma has a
partnering strategy for the development and commercialization of its products
and in addition to the collaboration with Sanofi in Type 2 diabetes, the
company has partnerships with Boehringer Ingelheim in diabetes/obesity, Abbott
in acute kidney injury and Helsinn Healthcare in chemotherapy induced diarrhea.
Zealand Pharma focuses its activities in disease areas where existing
treatments fail to adequately serve patient needs and where the market
potential for improved treatments through the use of peptide drugs is high.
About Bryan, Garnier
Bryan, Garnier & Co is an independent investment bank specialising in European TMT, Healthcare and Renewable Energies growth companies. Bryan, Garnier & Co is positioned in three activities: Equity Research & Brokerage, Asset Management and Corporate Finance.
With more than 120 professionals based in London, Paris, New York and Geneva, Bryan, Garnier & Co combines the range of services and the expertise of top-tier investment banks with the level of attention to clients of a boutique.
Through its corporate finance practice, Bryan, Garnier & Co has became a leader in advising European growth companies on strategic finance transactions such as mergers & acquisitions, equity capital market, LBOs and private placement over the last three years.
Bryan, Garnier & Co is authorized and regulated by the Financial Services Authority (FSA) in the United Kingdom, and is member of London Stock Exchange and Euronext, Alternext Listing Sponsor, and is active on all European capital markets.